What Is Rimso-50 and how is it used?
Rimso-50 (dimethyl sulfoxide, also called DMSO) is and anti-inflammatory and bladder irrigating drug believed to reduce swelling and pain due to interstitial cystitis and improve blood supply to the treated area used to treat pain and swelling associated with bladder or urinary conditions including cystitis (bladder inflammation or irritation).
What are side effects of Rimso-50?
Common side effects of Rimso-50 include bladder pain and discomfort. A garlic-like taste in the mouth may be noticed within minutes of placing Rimso-50 in the bladder. This taste may last several hours, and an odor on the breath or from the skin may be noticed for up to 3 days following use of Rimso-50.
STERILE AND NON-PYROGENIC
RIMSO-50® brand of dimethyl sulfoxide (DMSO) 50% w/w Aqueous Solution for intravesical instillation. Each mL contains 0.54 gm dimethyl sulfoxide. Intravesical instillation for the treatment of interstitial cystitis. NOT FOR I.M. OR I.V. INJECTION. Rx ONLY.
The active component of RIMSO-50® solution is dimethyl sulfoxide which has the empirical formula C2H6OS. Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3° C, and a specifc gravity of 1.096.
3 pharmacies near 20147 have coupons for Cryoserv (Brand Names:Rimso-50 for 50ML of 50%)
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
RIMSO-50® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.
DOSAGE AND ADMINISTRATION
Instillation of 50 mL of RIMSO-50® (dimethyl sulfoxide) directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately.
In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).
Vials contain 50 mL of sterile and non-pyrogenic RIMSO-50® (50% w/w dimethyl sulfoxide aqueous solution).
Dimethyl sulfoxide is clear and colorless.
carton containing a 50 mL vial
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from strong light.
For additional information concerning RIMSO-50®, contact Mylan Institutional LLC, Rockford, IL 61103.
Manufactured by: Mylan Institutional, Galway, Ireland. Revised: Apr 2018
A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50® (dimethyl sulfoxide). This taste may last several hours and because of the presence of metabolites, an odor on the breath and skin may remain for 72 hours.
Transient chemical cystitis has been noted following instillation of dimethyl sulfoxide.
The patient may experience moderately severe discomfort on administration. Usually this becomes less prominent with repeated administration.
No Information Provided
Drug Abuse And Dependence
Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50®. The physician should be cognizant of this possibility in prescribing RIMSO-50®. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
Changes in the refractive index and lens opacities have been seen in monkeys, dogs and rabbits given high doses of dimethyl sulfoxide chronically. Since lens changes were noted in animals, full eye evaluations, including slit lamp examinations, are recommended prior to and periodically during treatment.
Some data indicate that dimethyl sulfoxide potentiates other concomitantly administered medications.
Dimethyl sulfoxide caused teratogenic responses in hamsters, rats and mice when administered intraperitoneally at high doses (2.5 to 12 gm/kg). Oral or topical doses of dimethyl sulfoxide did not cause problems of reproduction in rats, mice and hamsters. Topical doses (5 gm/kg first two days, then 2.5 gm/kg - last eight days) produced terata in rabbits, but in another study, topical doses of 1.1 gm/kg days 3 through 16 of gestation failed to produce any abnormalities. There are no adequate and well controlled studies in pregnant women. Dimethyl sulfoxide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dimethyl sulfoxide is administered to a nursing woman.
Safety and effectiveness in children have not been established.
Information available to be given to the patient is reprinted at the end of this text.
The oral LD50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of RIMSO-50® in the patient.
Dimethyl sulfoxide is metabolised in man by oxidation to dimethyl sulfone or by reduction to dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces. Dimethyl sulfide is eliminated through the breath and skin and is responsible for the characteristic odor from patients on dimethyl sulfoxide medication. Dimethyl sulfone can persist in serum for longer than two weeks after a single intravesical instillation. No residual accumulation of dimethyl sulfoxide has occurred in man or lower animals who have received treatment for protracted periods of time. Following topical application, dimethyl sulfoxide is absorbed and generally distributed in the tissues and body fluids.
RIMSO-50® is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis.
RIMSO-50® will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician.
Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a RIMSO-50® instillation.
A garlic-like taste may be noted by the patient within a few minutes after instillation of RIMSO-50® (dimethyl sulfoxide). This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours.
Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration.
If you are pregnant or nursing, ask your physician about the advisability of using RIMSO-50®.
Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.